{"id":539037,"date":"2021-04-16T20:28:01","date_gmt":"2021-04-16T20:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=539037"},"modified":"2021-04-16T20:28:01","modified_gmt":"2021-04-16T20:28:01","slug":"parkinsons-disease-market-industry-analysis-pipeline-therapies-companies-and-forecast-by-delveinsight-impax-laboratories-luye-pharma-abbvie-living-cell-technologies-novartis","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/parkinsons-disease-market-industry-analysis-pipeline-therapies-companies-and-forecast-by-delveinsight-impax-laboratories-luye-pharma-abbvie-living-cell-technologies-novartis_539037.html","title":{"rendered":"Parkinson&#8217;s disease Market: Industry Analysis, Pipeline Therapies, Companies and Forecast by DelveInsight | Impax Laboratories, Luye Pharma, AbbVie, Living Cell Technologies, Novartis"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Parkinson&#039;s disease Market: Industry Analysis, Pipeline Therapies, Companies and Forecast by DelveInsight | Impax Laboratories, Luye Pharma, AbbVie, Living Cell Technologies, Novartis\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"Parkinson&#039;s disease Market: Industry Analysis, Pipeline Therapies, Companies and Forecast by DelveInsight | Impax Laboratories, Luye Pharma, AbbVie, Living Cell Technologies, Novartis\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Parkinson&#8217;s disease Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<strong>Parkinson&#8217;s Disease Market Insights, Epidemiology, and Market Forecast-2030&#8243;<\/strong>&nbsp;report delivers an in-depth understanding of the Parkinson&#8217;s Disease, historical and forecasted epidemiology as well as the Parkinson&#8217;s Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Parkinson&#8217;s Disease market size<\/a><\/strong> was&nbsp;USD 1837.90 million&nbsp;in 2017 in the 7MM.&nbsp; Among the 7 Major Markets,&nbsp;the United States&nbsp;accounted for the majority of the market size, with&nbsp;USD 941.13 million&nbsp;followed by&nbsp;Germany, which has the second-highest market size after&nbsp;the United States&nbsp;in 2017.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the facts of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Parkinson&#8217;s Disease total prevalent population in the 7MM countries was observed to be 1,608,367 in 2017 and is growing at a <strong>CAGR of 0.54%<\/strong> for the study period [2017&ndash;2028].<\/li>\n<li>Parkinson&#8217;s Disease total diagnosed prevalent population was 1,373,639 in 2017.<\/li>\n<li>Parkinson&#8217;s Disease diagnosed prevalent population was assessed to be the highest for&nbsp;the United States&nbsp;that accounts for 44.29% of the total patient pool among the 7MM countries.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/parkinsons-disease-market-size-analysis-treatment?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/parkinsons-disease-market-size-analysis-treatment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key benefits of the report<\/strong><\/p>\n<p style=\"text-align: justify;\">1.&nbsp;Parkinson&#8217;s Disease market report covers a detailed overview and comprehensive insight of the Parkinson&#8217;s Disease Epidemiology and Parkinson&#8217;s Disease market in the 7 MM (United States, EU5 (Germany,&nbsp;Spain,&nbsp;France,&nbsp;Italy, UK) &amp;&nbsp;Japan.)<\/p>\n<p style=\"text-align: justify;\">2.&nbsp;Parkinson&#8217;s Disease market report provides insights into the current and emerging Parkinson&#8217;s Disease therapies.<\/p>\n<p style=\"text-align: justify;\">3.&nbsp;Parkinson&#8217;s Disease market report offers a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n<p style=\"text-align: justify;\">4.&nbsp;Parkinson&#8217;s Disease market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Parkinson&#8217;s Disease market.<\/p>\n<p style=\"text-align: justify;\">&#8220;<strong><em>The age-specific prevalence data showed that the majority of the cases were diagnosed in the age-group of 65-84 years, followed by those aged 45-64 years in the 7MM countries.<\/em><\/strong>&#8220;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>The key&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Parkinson&#8217;s Disease market players<\/a>&nbsp;have the potential to create a significant positive shift in Parkinson&#8217;s Disease Market Size. Some of the companies involved are:-<\/strong><\/p>\n<p style=\"text-align: justify;\">1.&nbsp;&nbsp;&nbsp; US WorldMeds LLC<\/p>\n<p style=\"text-align: justify;\">2.&nbsp;&nbsp;&nbsp; Intec Pharma<\/p>\n<p style=\"text-align: justify;\">3.&nbsp;&nbsp;&nbsp; Sunovion Pharma<\/p>\n<p style=\"text-align: justify;\">4.&nbsp;&nbsp;&nbsp; Pharma&nbsp;Two B&nbsp;Ltd.<\/p>\n<p style=\"text-align: justify;\">5.&nbsp;&nbsp;&nbsp; Impax Laboratories<\/p>\n<p style=\"text-align: justify;\">6.&nbsp;&nbsp;&nbsp; Luye Pharma<\/p>\n<p style=\"text-align: justify;\">7.&nbsp;&nbsp;&nbsp; AbbVie<\/p>\n<p style=\"text-align: justify;\">8.&nbsp;&nbsp;&nbsp; Living Cell Technologies<\/p>\n<p style=\"text-align: justify;\">9.&nbsp;&nbsp;&nbsp; Novartis<\/p>\n<p style=\"text-align: justify;\">10.&nbsp;&nbsp; Neurocrine Biosciences<\/p>\n<p style=\"text-align: justify;\">And many others<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/d451b7a5fdef47aca09f7e91b0e3b361.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\"><strong>Get a free sample page : <\/strong><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/parkinsons-disease-market-size-analysis-treatment?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/parkinsons-disease-market-size-analysis-treatment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">There are currently no disease\u2010modifying drugs, but Parkinson&#8217;s Disease treatments are used to offer major symptomatic relief of the motor symptoms. They offer little benefit clinically in terms of the nonmotor manifestations. The present Parkinson&#8217;s Disease treatment options include surgery, medication, complementary and supportive therapies (such as diet, exercise, physical therapy, occupational therapy, and speech therapy). The approved medication therapies are categorized into seven groups that include Levodopa, Carbidopa\u2010levodopa infusion (Duodopa), Dopamine agonists, MAO B inhibitors, Catechol O\u2010methyltransferase (COMT) inhibitors, Anticholinergics and Amantadine. The drug to be used at the beginning of Parkinson&#8217;s Disease treatment is either levodopa or a dopamine agonist. L\u2010Dopa, a natural precursor of dopamine that is transformed in the brain into dopamine.<\/p>\n<p style=\"text-align: justify;\">Besides gene therapy, stem cell therapy have also shown a more effective Parkinson&#8217;s Disease treatment option. Stem cell research in Parkinson&#8217;s Disease is focusing on understanding nerve cells development and how healthy cells can be used to replace unhealthy brain cells.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>The expected launch of emerging therapies is believed to create a positive impact on Parkinson&#8217;s Disease market size in the upcoming years.<\/strong><\/p>\n<p style=\"text-align: justify;\">1. &nbsp;&nbsp;&nbsp;Apomorphine Infusion<\/p>\n<p style=\"text-align: justify;\">2.&nbsp;&nbsp;&nbsp; Accordion Pill Carbidopa\/Levodopa<\/p>\n<p style=\"text-align: justify;\">3.&nbsp;&nbsp;&nbsp; APL&ndash;130277<\/p>\n<p style=\"text-align: justify;\">4.&nbsp;&nbsp;&nbsp; P2B001<\/p>\n<p style=\"text-align: justify;\">5.&nbsp;&nbsp;&nbsp; IPX203<\/p>\n<p style=\"text-align: justify;\">6.&nbsp;&nbsp;&nbsp; LY03003<\/p>\n<p style=\"text-align: justify;\">7.&nbsp;&nbsp;&nbsp; ABBV\u2010951<\/p>\n<p style=\"text-align: justify;\">8.&nbsp;&nbsp;&nbsp; NTCELL Implantation<\/p>\n<p style=\"text-align: justify;\">9.&nbsp;&nbsp;&nbsp; Nilotinib<\/p>\n<p style=\"text-align: justify;\">10.&nbsp;&nbsp;&nbsp; VY\u2010AADC<\/p>\n<p style=\"text-align: justify;\">And many others<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/parkinsons-disease-market-size-analysis-treatment?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/parkinsons-disease-market-size-analysis-treatment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td valign=\"bottom\">\n<p><strong>1<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Parkinson&#8217;s Disease Key Insights<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>2<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Executive Summary of Parkinson&#8217;s Disease&nbsp;&nbsp;<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>3<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Parkinson&#8217;s Disease Market Overview at a Glance<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>4<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Parkinson&#8217;s Disease Case Reports&nbsp;<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>5<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Parkinson&#8217;s Disease&nbsp;Epidemiology and Patient Population<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>6<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Country Wise-Epidemiology of Parkinson&#8217;s Disease<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>6.1<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>The&nbsp;United States&nbsp;Epidemiology<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>6.2<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>EU5 Countries&nbsp;Epidemiology<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>6.2.1<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Germany<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>6.2.2<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>France<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>6.2.3<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Italy<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>6.2.4<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Spain<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>6.2.5<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>The United Kingdom<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>6.3<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Japan&nbsp;Epidemiology<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>7<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Treatment and Management of Parkinson&#8217;s Disease<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>8<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Parkinson&#8217;s Disease&nbsp;Unmet Needs<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>9<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Parkinson&#8217;s Disease&nbsp;Marketed Drugs<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>9.1<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Istradefylline (KW-6002): Kyowa Kirin<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>9.2<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Opicapone: BIAL<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>9.3<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Gocovri: Adamas Pharmaceuticals<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>9.4<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Xadago: Zambon SpA<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>9.5<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Osmolex ER: Osmotica Pharmaceutical<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>9.6<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Duopa (Duodopa, ABT-SLV187): AbbVie<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>9.7<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Rytary: Impax Laboratories (Amneal Pharmaceuticals)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>9.8<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Inbrija: Acorda Therapeutics<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>9.9<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Nuplazid: ACADIA Pharmaceuticals Inc.<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>10<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Parkinson&#8217;s Disease Emerging Drugs<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>10.1<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Apomorphine Infusion: US WorldMeds LLC<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>10.2<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Accordion Pill Carbidopa\/Levodopa: Intec Pharma<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>10.3<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>P2B001: Pharma Two B Ltd.<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>10.4<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>IPX203: Impax Laboratories (Amneal Pharmaceuticals)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>10.5<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>LY03003: Luye Pharma<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>10.6<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>ABBV-951: AbbVie<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>10.7<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Allo iPS cell-derived dopamine neural progenitor: Sumitomo Dainippon Pharma<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>10.8<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Solriamfetol (JZP-110): Jazz Pharmaceuticals<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>10.9<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>NBIb-1817 (VY-AADC): Neurocrine Biosciences\/Voyager Therapeutics<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>10.10<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>AAV-GAD: MeiraGTx Limited<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>10.11<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>AXO-Lenti-PD (OXB-102): Axovant Sciences<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>10.12<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>ND0612: NeuroDerm<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>10.13<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>ITI-214: Intracellular Therapies<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>10.14<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>IRL752: Integrative Research Laboratories AB (IRLAB)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>10.15<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>PR001: Prevail Therapeutics<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>10.16<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>ISC-hpNSC: International Stem Cell Corporation<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>11<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>7MM Parkinson&#8217;s Disease Market Analysis<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>11.1<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>The&nbsp;United States Parkinson&#8217;s Disease Market Size<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>11.2<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>EU-5 Parkinson&#8217;s Disease Market Size<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>11.2.1<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Germany Market Size<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>11.2.2<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>France Market Size<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>11.2.3<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Italy Market Size<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>11.2.4<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Spain Market Size<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>11.2.5<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>The United Kingdom Market Size<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>11.3<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Japan&nbsp;Parkinson&#8217;s Disease Market Size<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>12<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Parkinson&#8217;s Disease Market Drivers<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>13<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Parkinson&#8217;s Disease Market Barriers<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>14<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>SWOT Analysis of Parkinson&#8217;s Disease<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>15<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>KOL Views<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>16<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Parkinson&#8217;s Disease Market Access and Reimbursement<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>17<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Appendix<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>18<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>DelveInsight Capabilities<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>19<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Disclaimer<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>20<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>About DelveInsight<\/strong><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Deatiled TOC: https:\/\/www.delveinsight.com\/sample-request\/parkinsons-disease-market-size-analysis-treatment<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><br \/> DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=parkinsons-disease-market-industry-analysis-pipeline-therapies-companies-and-forecast-by-delveinsight-impax-laboratories-luye-pharma-abbvie-living-cell-technologies-novartis\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=parkinsons-disease-market-industry-analysis-pipeline-therapies-companies-and-forecast-by-delveinsight-impax-laboratories-luye-pharma-abbvie-living-cell-technologies-novartis\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Parkinson&#8217;s disease Market &nbsp; DelveInsight&#8217;s &#8220;Parkinson&#8217;s Disease Market Insights, Epidemiology, and Market Forecast-2030&#8243;&nbsp;report delivers an in-depth understanding of the Parkinson&#8217;s Disease, historical and forecasted epidemiology as well as the Parkinson&#8217;s Disease market trends in the United States, EU5 (Germany, Spain, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/parkinsons-disease-market-industry-analysis-pipeline-therapies-companies-and-forecast-by-delveinsight-impax-laboratories-luye-pharma-abbvie-living-cell-technologies-novartis_539037.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-539037","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/539037","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=539037"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/539037\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=539037"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=539037"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=539037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}